Related references
Note: Only part of the references are listed.The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
Amanda M. Johnson et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)
Systematic Review and Meta-Analysis of Observational Studies on the Effectiveness and Safety of Ustekinumab among Patients with Inflammatory Bowel Disease in Eastern and Western Countries
He Zhou et al.
JOURNAL OF CLINICAL MEDICINE (2023)
Effectiveness and safety of ustekinumab in bio-naive Crohn's disease patients: a multicentre observational retrospective study
Valdes Delgado Teresa et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)
Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases
Hongsheng Yang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis
Joseph Meserve et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
P433 Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc
M Garcia-Alvarado et al.
Journal of Crohns & Colitis (2022)
Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Sailish Honap et al.
DIGESTIVE DISEASES AND SCIENCES (2022)
Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis
Dahham Alsoud et al.
JOURNAL OF CROHNS & COLITIS (2022)
Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
Valerie Heron et al.
Journal of the Canadian Association of Gastroenterology (2022)
Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study
Tessa Straatmijer et al.
JOURNAL OF CROHNS & COLITIS (2021)
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy
Uri Kopylov et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease
Rahel Ehrenberg et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2020)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease
Yun Qiu et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease
C. Ma et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)